DYN
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)
Article Summary
HOLD- Dyne Therapeutics Inc. (NASDAQ: DYN) fell 9% after pricing a public offering of common stock expected to raise approximately $375 million, with the offering priced at $20.50 per share representing a discount of about 14% to Tuesday's closing price of $23.83, contributing to the decline in the stock.
- The biotechnology company priced an upsized offering of 18.3 million shares of commonstock, expected to generate gross proceeds of about $375.15 million before underwriting discounts, commissions, and other offering-related expenses, with all shares included in the offering being issued and sold by Dyne Therapeutics.
- The offering is scheduled to close on or around July 23, 2026 subject to satisfaction of customary closing conditions.
- Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers for the offering.
- Dyne granted the underwriting syndicate a 30-day option to purchase up to 2.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 15.4% | 25% | 50.0 ptsMeets Minimum (15.4%) - Passes screener |
| Target Price Upside ? | 75.4% | 20% | 100.0 ptsMassive Upside (75.4%) - Target: $39.33 vs Current: $22.42 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -10.3% | 15% | 40.0 ptsMild Pullback (-10.3%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.